VIBATIV Pregnancy Registry

Cumberland Pharmaceuticals

Status: Withdrawn

Conditions: Pregnancy

Treatments: Drug: VIBATIV

Study type: Observational

Funder types: Industry

Identifiers

NCT01130324

0113

Details and patient eligibility

About

The purpose of this registry is to evaluate the outcome of pregnancy in women exposed to VIBATIV at any time during pregnancy. There are no mandated physician visits for the registry.

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Female patients who were exposed to VIBATIV at any time during pregnancy
• Outcome of pregnancy is unknown at the time of enrollment

Trial design

0 participants in 1 patient group

VIBATIV treated pregnant women

Description:

Women treated with telavancin (any dose or duration) during pregnancy.

Treatment:

Drug: VIBATIV